Cerity Partners
GTBP icon

Cerity Partners’s GT Biopharma GTBP Stock Holding History

Cerity Partners’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.17K Buy
20,023
+5,023
+33% +$2.74K ﹤0.01% 3218
2025
Q4 		$11.8K Buy
+15,000
New +$10.7K ﹤0.01% 2858

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Cerity Partners's GTBP Position: Q1 2026 in Review

Cerity Partners increased its GT Biopharma (GTBP) stake by 33% in Q1 2026, buying an estimated $2.74K and bringing the position to 20,023 shares worth $8.17K. The position accounts for ﹤0.01% of the portfolio, ranked #3218.

Cerity Partners first reported a position in GTBP in Q4 2025 and has held it in 2 quarters since. The position peaked at $11.8K in Q4 2025. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Cerity Partners held 20,023 shares of GT Biopharma worth $8.17K as of Q1 2026.
  • Cerity Partners bought 5,023 GT Biopharma shares in Q1 2026, an estimated $2.74K.
  • GT Biopharma made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3218 holding.
  • Cerity Partners first reported a position in GT Biopharma in Q4 2025 and has held it in 2 quarters since.
  • Cerity Partners's GT Biopharma position peaked at $11.8K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.